Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15670601 | 1.00 | KMT2A (0.47) | KMT2AMEN1GAAALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL1362477 | 0.98 | KMT2A (0.46) | KMT2AMEN1GAAALDH1A1LMNA | |
| SCHEMBL9664845 | 0.87 | KMT2A (0.50) | KMT2AALDH1A1 | |
| SCHEMBL31059194 | 0.83 | PIN1 (0.42) | KMT2AMEN1GAAALDH1A1CES2 | |
| SCHEMBL15994532 | 0.83 | PIN1 (0.42) | KMT2AMEN1GAAALDH1A1CES2 | |
| SCHEMBL1274762 | 0.81 | ALDH1A1 (0.56) | KMT2AMEN1GAAALDH1A1LMNA | |
| SCHEMBL30059683 | 0.81 | ALDH1A1 (0.56) | KMT2AMEN1GAAALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL5967467 | 0.81 | PIN1 (0.45) | KMT2AMEN1GAAALDH1A1CES2 | |
| SCHEMBL23998738 | 0.80 | KMT2A (0.43) | KMT2AMEN1GAAALDH1A1CES2 | |
| SCHEMBL7976422 | 0.80 | CA1 (0.47) | KMT2AALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2912034-B1 | 3,4-DISUBSTITUTED OXAZOLIDINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE CALCIUM ACTIVATED POTASSIUM CHANNEL | HOFFMANN LA ROCHE (CH) | 2017-05-31 | — | — | EP | disclosed |
| US-9611232-B2 | Oxazolidinone and imidazolidinone compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20150246894-A1 | NOVEL OXAZOLIDINONE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-09-03 | — | — | US | disclosed |
| EP-2912034-A1 | 3,4-DISUBSTITUTED OXAZOLIDINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE CALCIUM ACTIVATED POTASSIUM CHANNEL | F. Hoffmann-La Roche AG (CH) | 2015-09-02 | — | — | EP | disclosed |
| WO-2014067861-A1 | 3,4-DISUBSTITUTED OXAZOLIDINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE CALCIUM ACTIVATED POTASSIUM CHANNEL | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246894-A1 | NOVEL OXAZOLIDINONE COMPOUNDS | OXA1L, CDK11B, CDK11A | KMT2A 1256/4885MEN1 1099/4885GAA 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.